Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2007-07-31
2007-07-31
Hoffman, Susan (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Reexamination Certificate
active
10754077
ABSTRACT:
Disclosed are methods and compositions useful in treating prostate cancer. The invention is based on BIRM, an extract of the plantSolanaceae-Dulcamaraand its previously unrecognized anti-prostate cancer activity. Also disclosed are methods for preparing compositions for administration to humans for treating prostate cancer.
REFERENCES:
patent: 4698360 (1987-10-01), Masquelier
patent: 6284289 (2001-09-01), Van den Berghe
patent: 6514538 (2003-02-01), Ota et al.
patent: 2002/0086894 (2002-07-01), Kindness et al.
Milot; HerbClip—www.physiologics.com/herbclip/review.asp?I=43917; 2004.
BIRM website (www.birm.com/shop/articles.htm—The Most Important Asset Now!—2002).
Cevallos (BIRM Carbohydrate of low molecular weight ECA 10-142 controls AIDS (1994) Tenth International Conference on Aids (Yokohama, Japan) Abstracts, vol. 2 (abstract No. 0291)).
Jacobson, Judith S., et al., “Complementary and Alternative Medicine in Prostate Cancer”,Curr Oncol Rep, (2001),3:448-42.
Jones, Heather A., et al., “Rates of Unconventional Medical Therapy use in Patients with Prostate Cancer: Standard History Versus Directed Questions”,Urology, (2002),59:272-276.
Kaighn, M. E., et al., “Establishment and Characterization of a Human Prostatic Carcinoma Cell Line (PC-3)”,Investigative Urology, (1979),17:16-23.
Wang, Min , et al., “Isolation and Characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice”,Differentiation, (1991),48:115-125.
Wenger, Allen S., et al., “In Vitro Characterization of MAT LyLu: A Dunning Rat Prostate Adenocarcinoma Tumor Subline”,The Journal of Urology, (1984),131:1232-1236.
Lokeshwar, Bal L., et al., “Inhibition of Cell Proliferation, Invasion, Tumor Growth and Metastasis by an Oral Non-Antimicrobial Tetracycline Analog (col. 3) in a Metastatic Prostate Cancer Model”,International Journal of Cancer, (2002),98:297-309.
Dudak, Scott D., et al., “Enhancement of Radiation Response of Prostatic Carcinoma by Lonidamine”,Anticancer Research, (1996),16:3665-3671.
Yamamura, Yasuhiro , et al., “A New Flow Cytometric Method for Quantitative Assessment of Lymphocyte Mitogenic Potentials”,Cellular and Molecular Biology, (1995),41:121-132.
Lokeshwar, Vinata B., et al., “Association of Elevated Levels of Hyaluronidase, a Matrix-degrading Enzyme, with Prostate Cancer Progression”,Cancer Research, (1996),56:651-657.
Block, Norman L., et al., “Stromal and Epithelial Expression of TUmor Markers Hyaluroinic Acid and HYAL1 Hyaluronidase in Prostate Cancer”,The Journal of Biological Chemistry, (2001),276:11922-11932.
Lokeshwar, Vinata B., et al., “Identificatin of Bladder Tumor-derived Hyaluronidase: Its SImilarity to HYAL1”,Cancer Research, (1999),59:4464-4470.
Bitter, Thomas , et al., “Mucopolysaccharides of Whole Human Spleens in Generalized Amyloidosis”,Journal of Clinical Investigation, (1966),45:963-975.
Harris, Katherine A., et al., “Treatment Options in Hormone-Refractory Prostate Cancer Current and Future Approaches”,Drug, (2001),61:2177-2192.
Kojima, Munekado , et al., “Use of Prostate-Specific Antigen and Tumor Volume in Predicting Needle Biopsy Grading Error”,Urology, (1995),45:807-812.
Mans, Dennis R., et al., “Anti-Cancer Drug Discovery and Development in Brazil: Targeted Plant Collection as a Rational Strategy to Acquire Candidate Anti-Cancer Compounds”,The Oncologist. (2000),5:185-198.
Pienta, Kenneth J., et al., “Effect of Estramustine, Etoposide, and Taxol on Prostate Cancer Cell Growth In Vitro and In Vivo”,Urology, (1996),48:164-170.
Lokeshwar, Balakrishna L., et al., “Secretion of Matrix Metalloproteinases and Their Inhibitors (Tissue Inhibitor of Metalloproteinases) by Human Prostate in Explant Cultures: Reduced Tissue Inhibitor of Metalloproteinase Secretion”,Cancer Research, (1993),53:4493-4498.
Smith, Michael , et al., “Select Complementary/Alternative Therapies for Prostate Cancer The Benefits and Risks”,Cancer Practice, (2001),9:253-255.
Dandekar, Devendra S., et al., “An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis”,Cancer Chemotherapy and Pharmacology, (2003),52:59-66.
Harvey Wickes Felter, M.D. et al., “King's American Dispensatory” Homepage website, http://www.henriettesherbal.com/electic/kings/index.html, (Feb. 8, 2002).
John T. Cutis et al., “Wisconsin Botancia Information System (WIBIS)”, http://www.botany.wisc.edu/wisflora/scripts/details.asp??SpCode=SOLDUL, pp. 1-2.
USDA Natural Resources Conversation Service (USDA-NRC), http://www.plants.usda.gov/java.profile?symbol=SODU, pp. 1-2/4.
Plant Atlas by USF; http://www.plantatlas.usf.edu/plantimage/solanum—dulcamara.jpg, color picture.
Plant Atlas by USF; http://www.plantatlas.usf.edu/plantimage/solanum—dulcamara.jpg, color picture.
Plant Atlas by USF; http://www.plantatlas.usf.edu/plantimage/solanum—dulcamara.jpg, color picture.
Gary A. Scott, Printout from garyascott.com website, http://www.garyascott.com, Make, enjoy and Keep Wealth, 1968-2006.
Fox Rothschild LLP
Hoffman Susan
Norton Gerard P.
Sharareh Shahnam
LandOfFree
Anti-prostate cancer composition and therapeutic uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-prostate cancer composition and therapeutic uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-prostate cancer composition and therapeutic uses therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3795345